Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 11,591 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Chronic Traumatic Brain Injury
Interventions: Anti-inflammatory Diet, N-acetyl Cysteine, Neuro Emotive Technique; Other · Dietary Supplement · Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Villanova, Pennsylvania

Conditions: Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions: Renal Autologous Cell Therapy (REACT); Biological
Lead sponsor: Prokidney; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pegylated liposomal doxorubicin hydrochloride, picoplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pain, Depression, Anxiety, Opioid Use
Interventions: myStrength; Behavioral
Lead sponsor: MyStrength, Inc.; Other
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more

Conditions: Hepatitis C, Chronic
Interventions: PEGylated recombinant interleukin 29 (PEG-rIL-29); Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Chicago, Illinois • Detroit, Michigan • Rochester, Minnesota + 6 more

Conditions: Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox
Interventions: CAT-8015 5 mcg/kg, CAT-8015 10 mcg/kg, CAT-8015 20 mcg/kg; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Indianapolis, Indiana • Bethesda, Maryland

Conditions: Anxiety
Interventions: Anxiety Self-Management, Patient preferred relaxing music, Control 1: Noise-cancelling headphones, Control 2: Standard of Care; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD)
Interventions: PLS240, Placebo, Open-Label Extension PLS240; Drug
Lead sponsor: Pathalys Pharma; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 49
States / cities: Pine Bluff, Arkansas • Anaheim, California • Beverly Hills, California + 41 more

Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Interventions: UB-VV111, rapamycin; Genetic · Drug
Lead sponsor: Umoja Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 7
States / cities: Duarte, California • Chicago, Illinois • Grand Rapids, Michigan + 4 more

Conditions: Chronic Kidney Diseases
Interventions: Best practice alert and order set for CKD; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Anemia of Chronic Kidney Disease
Interventions: vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 4 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: Secukinumab (AIN457), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more

Conditions: Depression, Anxiety, Stress Related Disorder, Adjustment Disorders
Interventions: Mindfulness Training for Primary Care, 60-minute Introduction to Mindfulness; Behavioral
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: azacitidine, sodium phenylbutyrate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID Long-Haul
Interventions: [11C]CPPC Injection; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Foot Ulcer
Interventions: Folinic acid calcium salt; Combination Product
Lead sponsor: Joseph Boykin, MD; Federal
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Leukemia
Interventions: rituximab, lenalidomide; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Interventions: Bariatric surgery; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Posttraumatic Stress Disorder
Interventions: Mobile Web App; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Colorado Springs, Colorado • Chapel Hill, North Carolina

Conditions: Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
Interventions: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin; Device · Drug
Lead sponsor: HillMed Inc.; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cerebral Palsy
Interventions: Gait Therapy; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 13 Years to 18 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boys Town, Nebraska

Conditions: COPD
Interventions: PT010 Dose 1, PT010 Dose 2, Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetic Foot Ulcer
Interventions: Dermal - Living Skin Replacement (Dermal - LSR); Device
Lead sponsor: ApoPharma; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Tuscon, Arizona • Mather, California • San Diego, California + 8 more

Conditions: Chronic Low Back and Leg Pain
Interventions: Not listed
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Edina, Minnesota • Garland, Texas

Search by objective public record fields.

PET-MRI in Chronic Traumatic Brain Injury (CTBI)

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Digital Tools for Coping With Chronic Pain

Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Anxiety Self-Management for ICU Patients Receiving Mechanical Ventilation

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Pragmatic Trial of Messaging to Providers About Treatment of Chronic Kidney Disease

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 2)

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Long COVID-19 [11C]CPPC Study

Evaluation of a Folic Acid Wound Treatment (FAWT) for Chronic, Early-Stage Diabetic Foot Ulcer (DFU) Healing

Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity

Testing of a Mobile Web App to Decrease Posttraumatic Stress Symptoms in Women After Sexual Assault

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

Igniting Mobility in Adolescents and Young Adults With Cerebral Palsy

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

Spinal Cord Stimulation Research Study